These findings suggest the possible immune therapy for cancer using genotoxic agents by enhancing the susceptibility to TRAIL-bearing cytotoxic T, NK, NKT, dendritic cells and monocytes as well as administration of soluble TRAIL. The gene discussed is TNFSF10; the disease is cancer.